Results 81 to 90 of about 10,513,249 (295)

Glucocorticoid exposure and initiation of SSRIs among patients with rheumatoid arthritis: A nested case–control study in UK primary care

British Journal of Clinical Pharmacology, EarlyView.
Aim The immune system might affect the development of anxiety disorders, though mechanisms remain unclear. This nested case–control study investigates whether use of glucocorticoids, potent immunosuppressants, is associated with SSRI initiation (a proxy for pharmacologically treated mental disorders, predominantly depression and/or anxiety).
Elise J. Heesbeen, Patrick C. Souverein, Eibert R. Heerdink, Elisabeth Y. Bijlsma, Lucianne Groenink   +4 more
wiley   +1 more source

Hepatitis C care delivery practices among buprenorphine prescribers and non-prescribers: results from a survey of Washington state primary care providers

Addiction Science & Clinical Practice
Background Hepatitis C infection (HCV) and opioid use disorder (OUD) are syndemic in the U.S., thus primary care providers (PCPs) who treat OUD by prescribing buprenorphine can play key roles to advance HCV elimination targets.
Jocelyn R. James, Amelia M. Mohabir, Claire B. Simon, Allison Cole, Emalie Huriaux, Jon Stockton, Julien Rouvere, Judith I. Tsui   +7 more
doaj   +1 more source

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)-VK4-116, as a Non-Opioid Medication for the Treatment of Opioid Use Disorder. [PDF]

Med Res Rev
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Wu CK, Lin YC, Huang J, Ding B, Terse P, Nandre R, Jin H, Congdon M, Shen K, Sanderson P, Tawa G, Mounaud S, Santis M, Lo D, Ottinger EA, Newman AH.   +15 more
europepmc   +2 more sources

Update on the clinical use of buprenorphine: in opioid-related disorders.

Canadian family physician Medecin de famille canadien, 2012
To review the current evidence on buprenorphine-naloxone for the treatment of opioid-related disorders, with a focus on primary care settings.MEDLINE and the Cochrane Database of Systematic Reviews were searched. Evidence is mainly level I.Buprenorphine is a partial μ-opioid agonist and κ-opioid antagonist with a long half-life and less abuse potential
Simon, Ducharme, Ronald, Fraser, Kathryn, Gill   +2 more
openaire   +1 more source

Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016

Journal of Substance Abuse Treatment, 2020
Opioid medication treatment access is a public health priority aimed to improve opioid use treatment outcomes. However, Medicaid does not cover all forms of MOUD, particularly methadone, in many states. We examined associations between medication for opioid use disorder (MOUD) plans and substance use treatment discharge reason (e.g., completed ...
Melanie S, Askari, Silvia S, Martins, Pia M, Mauro   +2 more
openaire   +3 more sources

Paediatric clonidine medication errors: Findings from a multicentre French study

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to describe the characteristics of medication errors involving clonidine in paediatric patients and reported to French Network of Pharmacovigilance and Poison Control Centres. Methods This retrospective observational study analysed clonidine‐related medication errors reported between 1985 and June 2024 in patients under 12 years ...
Eve‐Marie Thillard, Anthony Facile, Marion Lepelley, Morgane Cellier, Laurent Chouchana, Sophie Gautier, Ramy Azzouz, Thierry Vial, Annie‐Pierre Jonville‐Bera   +8 more
wiley   +1 more source

Safety of opioid patch initiation in Australian residential aged care [PDF]

, 2015
Explores opioid use by aged care facility residents before and after initiation of transdermal opioid patches. Abstract Objective: To explore opioid use by aged care facility residents before and after initiation of transdermal opioid patches. Design:
Lisa Pont, Svetla Gadzhanova, Elizabeth Roughead, Roughead, E.E., Pont, L.G., Gadzhanova, S.   +5 more
core   +1 more source

Histamine and the mechanisms of nausea and vomiting: Translating the uncertain pharmacology of cyclizine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley   +1 more source

Comparison of early maladaptive schemas and parenting origins in patients with opioid abuse and non-abusers. [PDF]

Iranian Journal of Psychiatry, 2011
Objective: The aim of this study was to examine the difference of early maladaptive schemas and parenting origins in opioid abusers and non-opioid abusers.
Mohammad Reza Jalali, Mohammad Zargar, Mojgan Salavati, Ali Reza Kakavand   +3 more
doaj   +1 more source

Pharmacoepidemiology of Oxycodone in the USA: An Observational Study of ARCOS, Medicaid, and Medicare Drug Databases

Pharmacology Research & Perspectives
The US continues to battle an opioid crisis, substantially influenced by prescription opioids, with nearly 80 000 opioid‐related deaths in 2023. This study aims to characterize oxycodone's distribution in the United States (US) from 2000 to 2023 using ...
Jay P. Solgama, Apoorva Pradhan, Kenneth L. McCall, Brian J. Piper   +3 more
doaj   +1 more source